Kite Reports Primary Overall Survival Analysis Results Of Phase 3 ZUMA-7 Study

Kite, a Gilead Company (GILD), announced the primary overall survival analysis
results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in overall survival versus historical treatment, which was the standard of care in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma within 12 months of completion of first-line therapy.

ZUMA-7 was conducted under a Special Protocol Assessment with the FDA. ZUMA-7 is the first Phase 3 study of any CAR T-cell therapy, with the longest follow-up, which has showed event-free survival, the primary endpoint, that is superior to historical
SOC treatment. Data from the ZUMA-7 trial led to the U.S. approval for initial treatment of R/R LBCL in April 2022 and European Union approval in October 2022.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
GameStop Corp. Wednesday disclosed that its Board of Directors has elected Chairman Ryan Cohen as Executive Chairman, effective immediately. In a filing with the U.S. Securities and Exchange Commission, the video game retailer said its Board on June 5 terminated Matthew Furlong as President and Chief Executive Officer with immediate effect. Shares of Inditex SA were gaining around 6 percent in the morning trading in Spain after the clothing firm that owns Zara reported Wednesday significant growth in its first-quarter profit on higher revenues as well as the absence of a prior year provision. Regarding the second quarter to date, the company said its store and online sales in constant currency between May 1 and June 4 increased 16.. The U.S. Consumer Product Safety Commission or CPSC, along with Golden, Colorado-based Boppy Co., urged consumers to stop using recalled Boppy Newborn Loungers, following reports of more infant deaths. They also asked online marketplaces to stop selling the recalled product. The company in September 2021 had recalled over 3.3 million infant lounging pillows after it was connected with deaths of 8
Follow RTT